Acción Inozyme Pharma (INZY)
Empresa del sector salud. Aquí tienes el precio, un resumen del negocio y lo que conviene saber sobre Inozyme Pharma en septiembre 2026.
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
